-2.19%
10.50%
13.39%
4.87%
174.42%
236.38%
271.42%
AI Spotlight on INSM
Company Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders.
Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Market Data
| Last Price | 76.29 |
| Change Percentage | -2.19% |
| Open | 78.8 |
| Previous Close | 78 |
| Market Cap ( Millions) | 13649 |
| Volume | 2366985 |
| Year High | 80.63 |
| Year Low | 21.92 |
| M A 50 | 72.21 |
| M A 200 | 64.14 |
Financial Ratios
| FCF Yield | -4.66% |
| Dividend Yield | 0.00% |
| ROE | 1259.44% |
| Debt / Equity | 206.83% |
| Net Debt / EBIDTA | -70.24% |
| Price To Book | 27.42 |
| Price Earnings Ratio | -15.33 |
| Price To FCF | -21.46 |
| Price To sales | 39.8 |
| EV / EBITDA | -18.51 |
News
- Jan -10 - Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference
- Jan -03 - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Jan -02 - Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Dec -23 - 5 Biotech Breakthrough Stocks to Watch in 2025
- Dec -06 - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Dec -02 - Insmed To Present at December 2024 Investor Conferences
- Nov -20 - Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data
- Nov -07 - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Nov -06 - Insmed To Present at November 2024 Investor Conferences
- Nov -04 - Insmed (INSM) Reliance on International Sales: What Investors Need to Know
- Nov -01 - Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates
- Oct -31 - Insmed Incorporated (INSM) Q3 2024 Earnings Call Transcript
- Oct -31 - Insmed (INSM) Reports Q3 Earnings: What Key Metrics Have to Say
- Oct -31 - Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
- Oct -31 - Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update
- Oct -30 - Insmed (INSM) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
- Oct -24 - Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List
- Oct -23 - Insmed Unites Across Communities Around the World During Third Annual Global Day of Good
- Oct -17 - Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024
- Oct -08 - New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Therapies
Expected Growth : 8.97 %
What the company do ?
Insmed Incorporated's therapies focus on treating rare and serious diseases, including ARIKAYCE for refractory Mycobacterium avium complex lung disease.
Why we expect these perspectives ?
Insmed's therapies, such as Arikayce, are driving growth due to increasing adoption in treating refractory Mycobacterium avium complex (MAC) lung disease. Strong sales momentum, expanded commercial presence, and growing demand for orphan drugs are contributing to the 8.97% growth rate.
Insmed Incorporated Products
| Product Range | What is it ? |
|---|---|
| Arikayce | Arikayce is a liposomal formulation of amikacin, an aminoglycoside antibiotic, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in adults. |
Insmed Incorporated's Porter Forces
Threat Of Substitutes
Insmed Incorporated has a moderate threat of substitutes due to the availability of alternative treatments for respiratory diseases.
Bargaining Power Of Customers
Insmed Incorporated has a low bargaining power of customers due to the lack of negotiating power of individual patients.
Bargaining Power Of Suppliers
Insmed Incorporated has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials.
Threat Of New Entrants
Insmed Incorporated has a high threat of new entrants due to the attractiveness of the respiratory disease treatment market.
Intensity Of Rivalry
Insmed Incorporated operates in a highly competitive market with several established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 138.06% |
| Debt Cost | 6.31% |
| Equity Weight | -38.06% |
| Equity Cost | 8.60% |
| WACC | 5.44% |
| Leverage | -362.73% |
Insmed Incorporated : Quality Control
Insmed Incorporated passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| IDYA | IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product … |
| TECH | Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, … |
| ADMA | ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. … |
| BBIO | BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging … |
| ALPN | Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Alpine Immune Sciences
A-Score
1-Year Total Return ->
🥈
Bio-Techne
A-Score
1-Year Total Return ->
🥉
ADMA Biologics
A-Score
1-Year Total Return ->
4
Insmed
A-Score
1-Year Total Return ->
5
BridgeBio Pharma
A-Score
1-Year Total Return ->
6
